How deadly is Prostate cancer?

Kasano kasaknap ti makapapatay a kanser ti prostate?

Ti kanser ti prostate ti maikadua a kaaduan a kanser kadagiti lallaki iti intero a lubong, nga adda mapattapatta a 1.276 a milion a baro a kaso a naireport idi 2018, a mangirepresentar iti 7.1% iti amin a kaso ti kanser kadagiti lallaki.

Nangato met ti bilang dagiti matmatay iti kanser ti prostate, ta mapattapatta nga adda 37,005 a natay iti intero a lubong idi 2018.

Nupay kasta, dakkel ti nagdumaan ti bilang dagiti matmatay iti kada rehion, ta ti Makinlaud nga Africa ti maikalima a kadakkelan ti posibilidadna a matay iti kanser ti prostate iti lubong, ket ti Nigeria ti kadakkelan ti populasion ken ekonomia iti daytoy a rehion.

Idiay Nigeria, ti kanser ti prostate ti kadawyan ken makapapatay unay a kanser kadagiti lallaki, nga adda mapattapatta a 32.8 a kaso ken 16.3 a matmatay iti kada 100,000 a lallaki.

Daytoy ket nasurok a mamindua iti bilang dagiti matmatay idiay Amianan nga America.

Ti naladaw a pannakatakuat iti sakit, limitado a pamastrekan iti panangsukimat ken panangilasin, ken ti bimmassit a dokumentasion ken panangipadamag kadagiti kaso ti makagapu iti nangato a bilang dagiti matmatay idiay Nigeria.

Idiay Estados Unidos, ti kanser ti prostate ti maikadua a kadawyan a pakaigapuan ti ipapatay dagiti lallaki gapu iti kanser, nga agarup 40,0000 a lallaki ti matay iti sakit iti kada tawen.

Ti bilang dagiti matmatay iti kanser ti prostate ket in-inut a bimmassit sipud idi rugrugi ti dekada 1990, ngem agtalinaed a dakkel a pakaseknan iti salun-at.

Kaaduanna, makapapatay ti kanser ti prostate, nangruna kadagiti rehion a limitado ti magun-odan a panangagas ken pamay-an ti pannakaeksamen.

Nupay kasta, ti nasapa a panangilasin ken panangagas dakkel ti maitulongna tapno sumayaat ti resulta ken makissayan ti bilang dagiti matmatay.

['Dagiti reperensia']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.

Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.

Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.

Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.

Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.

['Disclaimer: medikal']

['Daytoy a website ket maipaay laeng a pangisuro ken pakaammuan ken saan a mangipaay iti medikal a balakad wenno propesional a serbisio.']

['Ti naited nga impormasion ket saan a rumbeng a mausar a pangdayagnos wenno pangagas iti sakit, ket dagidiay agbirbirok iti personal a medikal a balakad rumbeng nga agkonsultada iti lisensiado a doktor.']

['Pangngaasiyo ta laglagipenyo a ti neural net a mangpataud kadagiti sungbat kadagiti saludsod ket saan a husto no maipapan iti numeriko a linaon. Kas pagarigan, ti bilang dagiti tattao a nadayagnos nga addaan iti espesipiko a sakit.']

['Kanayon nga agpabalakadka iti doktormo wenno iti sabali a kualipikado a mangay-aywan iti salun-at maipapan iti kasasaadmo. Dimo pulos baybay-an ti propesional a balakad ti doktor wenno itantan ti agpabalakad gapu iti nabasam iti daytoy a website. No ipagarupmo nga adda emerhensia a kasapulam, tumawagka iti 911 wenno mapanka a dagus iti kaasitgan nga emergency room. Awan ti relasion ti doktor ken pasiente gapu iti daytoy a website wenno ti panangusar iti dayta. Saan a mangirepresentar ti BioMedLib wenno dagiti empleadona, wenno ti asinoman a tumultulong iti daytoy a website, iti aniaman a direkta wenno saan a direkta, mainaig iti impormasion a naited ditoy wenno iti pannakausarna.']

['Disclaimer: karbengan ti kopia']

['Ti Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (ti DMCA) mangipaay iti pamuspusan para kadagiti makinkukua iti copyright a mamati a ti material a makita iti Internet salungasingenna dagiti kalinteganda iti sidong ti linteg ti copyright ti E.U. ']

['No patiem a naimbag ti nakemmo a ti aniaman a linaon wenno material a naikabil mainaig iti website wenno serbisiotayo salungasingenna ti copyright-mo, mabalinmo (wenno ti ahentem) ti mangipaima kadakami iti pakaammo a mangkiddaw a maikkat ti linaon wenno material, wenno malapdan ti panagusar iti dayta. ']

['Dagiti pakaammo masapul a maipatulod iti surat babaen ti e-mail (kitaen ti benneg a "Kontak" para iti e-mail address). ']

['Kalikaguman ti DMCA a ti pakaammoyo iti maipagarup a panaglabsing iti copyright ramanenna dagiti sumaganad nga impormasion: (1) deskripsion ti copyrighted a trabaho a suheto ti maipagarup a panaglabsing; (2) deskripsion ti maipagarup a linaon a manglabsing ken impormasion nga umdas a mangipalubos kadakami a mangbirok iti linaon; (3) impormasion a pangkontakan kadakayo, agraman ti adresyo, numero ti telepono ken email address; (4) deklarasionyo a patienyo a ti linaon iti wagas a naireklamo ket saan nga impalubos ti akinkukua iti copyright, wenno ti ahentena, wenno babaen ti aniaman a linteg; ']

['(5) maysa a deklarasionyo, a pinirmaanyo iti sidong ti dusa a panagsaksi iti ulbod, a ti impormasion iti pakaammo ket umiso ken adda autoridadyo a mangipatungpal kadagiti copyright a makuna a nasalungasing; ']

['ken (6) pisikal wenno elektroniko a pirma ti makinkukua iti copyright wenno ti tao a napalubosan nga agtignay para iti makinkukua iti copyright. ']

['No saan a mairaman amin nga impormasion a nadakamat iti ngato, mabalin a maitantan ti pannakataming ti reklamoyo.']

['Kontak']

['Pangngaasiyo ta patulodandakami iti email iti aniaman a saludsod/singasing.']

How deadly is prostate cancer?

Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.

The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.

However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.

In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.

This is more than double the death rate in North America.

Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.

In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.

The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.

Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.

However, early detection and treatment can significantly improve outcomes and reduce mortality rates.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.